<- Go Home

Perrigo Company plc

Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. It also offers healthy lifestyle products, such as smoking cessation and well-being products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women’s health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; rare diseases business; and other miscellaneous self-care products. The company sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, and Compeed brands. It also offers contract manufacturing services. The company sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.

Market Cap

$3.8B

Volume

1.5M

Cash and Equivalents

$409.9M

EBITDA

$802.6M

Tax Rate Collected

N/A

Tax Rate Ratio

N/A

Gross Profit

$1.6B

Profit Margin

36.38%

52 Week High

$30.93

52 Week Low

$23.14

Dividend

4.21%

Price / Book Value

0.87

Price / Earnings

-22.93

Price / Tangible Book Value

-2.56

Enterprise Value

$7.2B

Enterprise Value / EBITDA

8.47

Operating Income

$478.2M

Return on Equity

3.64%

Return on Assets

2.93

Cash and Short Term Investments

$409.9M

Debt

$3.8B

Equity

$4.4B

Revenue

$4.3B

Unlevered FCF

$503.1M

Sector

Pharmaceuticals

Category

N/A

Hedge Funds that own this stock

PREMIUM

Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).

Upgrade to Yellowbrick Premium

Yellowbrick Portfolios that own this stock

PREMIUM

Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).

Upgrade to Yellowbrick Premium

Company Stock Pitches